论文部分内容阅读
目的:观察三芪口服液对慢性肾衰竭大鼠血小板膜糖蛋白(CD62P)表达的影响。方法:将SD大鼠随机分为空白对照组、模型对照组、包醛氧淀粉组,及三芪口服液治疗高、中、低剂量组(TMH、TMM、TML组)。观察12周,检测大鼠血尿素氮(BUN)、血肌酐(Scr)、血红细胞压积(HCT)、血小板计数(PLT)和CD62P的表达。结果:三芪口服液治疗后,与模型组比较能降低BUN、Scr值,下调CD62P,差异具有统计学意义(P<0.05)。结论:三芪口服液在一定程度上可下调CD62P的表达,这可能是其改善肾功能的机制之一。
Objective: To observe the effect of Sanqi Oral Liquid on the expression of platelet membrane glycoprotein (CD62P) in rats with chronic renal failure. Methods: SD rats were randomly divided into blank control group, model control group, saline group and Sanqi oral liquid for high, medium and low dose groups (TMH, TMM, TML group). After 12 weeks, the blood levels of BUN, Scr, HCT, PLT and CD62P were detected. Results: After treated with Sanqi Oral Liquid, BUN and Scr decreased and CD62P decreased compared with the model group, the difference was statistically significant (P <0.05). Conclusion: Sanqi Oral Liquid can down-regulate the expression of CD62P to a certain extent, which may be one of the mechanisms to improve renal function.